How Revitalist Provides Access To Treatment With Its Own Insurance Company

CEO Kathryn Walker of Revitalist Lifestyle and Wellness (CSE: CALM, OTC: RVLWF, FSE: 4DO) joined The Dales Report aboard the Maryam in Miami, Florida, to catch viewers up on the latest news from the Knoxville, Tennessee-based company. 

Like other public companies in the space, Revitalist made an appearance at the Wonderland: Miami conference, where Walker said she was thrilled to see a diverse crowd in attendance.

“There are a lot of investors, a lot of public companies here, and a lot of heavy hitters in the space,” she said, “but there’s also your general population, and they’re just ready. There’s a revolution ready to happen.”

Walker noted her team has met with a lot of people in the space with a focus on drug development, who are keen on the company’s clinic structure. 

“The way we set up our clinics is that we have the professionals there that can take on anything that gets to the surface,” she said. “A lot of drug developers that we’ve had meetings with, and biotech companies, bankers, and investors. We’re creating the infrastructure for a whole new system.”

Walker, who has an extensive background in the healthcare system in the United States, had some good things to say about the emerging psychedelic space, but also suggested a few ways for it to improve.

“I think open-mindedness is the right way,” she said. “As this is so new, we’re going to have to shift a little bit to the traditional system, because the traditional system is not going to go away. We’ve just got to learn how to upgrade it.”

Millennial entrepreneur and investor Anthony Varrell is an investor in the company and said what drew him to Revitalist was Walker’s role as one of the only female CEOs in the industry.

More than being one of very few women in executive roles, Walker said, her two decades in the medical space working in the ICU have been crucial to her role at Revitalist. Her background has informed the company’s decision to build their own in-house insurance team.

“A lot of people at the company said, ‘stay as far away from insurance as you can,’ because they know how hard it is. But everyone needs access to this,” she said.

Walker pointed out that the current response rate to anti-depressants like SSRIs is 30 percent, around the same as placebo—while response rates to psychedelic treatment are closer to 70 percent. And with the street drug supply tainted with drugs like fentanyl, self-medicating has become a potentially deadly solution. 

“We’re able to increase access, and have people come to a safe place where they don’t have to worry about who’s cutting the drugs on the street… and then if something happens, we’re there to help them. It’s pushing very aggressively to make access available to everybody.”

Check out the interview in its entirety in the video above. 

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More